Navigation Links
Forge Therapeutics Announces Novel Antibiotic Presentation at the American Society of Microbiology Conference on Antibacterial Development
Date:12/12/2016

SAN DIEGO, Dec. 12, 2016 /PRNewswire/ -- Forge Therapeutics, Inc. announced today that new preclinical data on its novel class of antibiotic targeting LpxC for treating infections by Gram-negative drug resistant bacteria will be presented at the American Society of Microbiology Conference held in Washington, DC from December 11-14, 2016.

Presentation details:


Conference Title:

ASM Conference on Antibacterial DevelopmentPoster presentation:

Monday, December 12 from 7:00pm to 8:30pmPoster title:

#35 Antimicrobial activity of non-hydroxamate LpxC inhibitorsConference location:

Omni Shoreham Hotel
2500 Calvert Street, NM,
Washington, DC 20008

Conference website:   http://conferences.asm.org/index.php/upcoming-conferences/asm-conference-on-antibacterial-development

About LpxC
Drug resistant Gram-negative bacteria are regarded as an extremely dangerous public health threat, therefore, novel antibiotics targeting Gram-negative bacteria are desperately needed. LpxC is a highly sought after target only found in Gram-negative bacteria.  Forge has discovered novel small molecule inhibitors of LpxC that are potent in vitro, efficacious and tolerated in vivo, and effective against drug resistance mechanisms including mcr-1, KPC, and NDM.  

About Forge Therapeutics, Inc.
Forge Therapeutics, Inc. ("Forge") is a biotechnology start-up that leverages its novel chemistry platform to develop small molecule inhibitors to target metalloproteins.  Metalloproteins are proteins that require metal ions for their biological function and make up over 1/3 of the proteins in the human body.  Forge uses a proprietary approach comprised of molecular modeling for rational drug design along with fundamental knowledge and expertise in bioinorganic chemistry to target metalloproteins.  The name Forge Therapeutics comes from two definitions for forge: to manipulate (inhibit) a metal object (metalloprotein) and to move forward steadily with a purpose (the Forge team).  Forge Therapeutics, Inc., maintains its headquarters in San Diego, California.  To learn more please visit www.ForgeTherapeutics.com.

Contact:
Info@ForgeTherapeutics.com

Logo - http://photos.prnewswire.com/prnh/20150807/256906LOGO

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/forge-therapeutics-announces-novel-antibiotic-presentation-at-the-american-society-of-microbiology-conference-on-antibacterial-development-300376235.html


'/>"/>
SOURCE Forge Therapeutics, Inc.
Copyright©2016 PR Newswire.
All rights reserved


Related biology technology :

1. Don't Forget the Payer in Your Digital Strategy: What Payers Need and Want from Pharma
2. Tor/Forge Launches THE CURE, a Riveting Thriller in the Tradition of Michael Crichton, by the New York Times Bestselling Author of WIRED.
3. Never forget a face
4. Bynder and HubCast Forge Global Partnership for Transformative “Concept to Delivery” Solution
5. Genedata and IntelliCyt Forge Alliance to Transform Cell-based Screening in Drug Discovery
6. Forge Therapeutics Enters Into a Pilot Study with Janssen Research & Development, LLC, to Discover Novel Metalloprotein Inhibitors
7. Forge Therapeutics Co-Founder to Present at the 250th American Chemical Society National Meeting
8. Forge Therapeutics Scientific Co-Founder Bestowed Prestigious National Chemistry Award
9. PointCross Life Sciences And Smithers Avanza Forge Strategic Partnership For SEND Solutions
10. Childhood Leukemias Forged by Different Evolutionary Forces than in Older Adults
11. Peptide Therapeutics Market is Expected to Reach USD 25.4 Billion Globally in 2018: Transparency Market Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... ... 2017 , ... Resoundant, Inc. is pleased to introduce ... U.S. that offer MR Elastography for liver fibrosis staging. MR Elastography is ... liver fibrosis assessment. , “MRE:connect was created in response to an increasing number ...
(Date:7/20/2017)... and PLYMOUTH, Minn., July 20, 2017 /PRNewswire/ ... , a personalized genetic evaluations company, today announced ... their partnership investigating a genetic mutation implicated in ... extend the partnership for a second case involving ... year, the KCNQ2 Cure Alliance and Pairnomix entered ...
(Date:7/18/2017)... (PRWEB) , ... July 18, 2017 , ... ... today announced that Merck, a leading science and technology company, has implemented ... therapeutics for the therapeutic areas of Oncology, Immunology, and Neurodegenerative Diseases. , The ...
(Date:7/17/2017)... ... ... Whitehouse Laboratories is excited to announce that it has ... ISO 80369 standard test procedures. The ISO 80369 series of eight test standards ... this recent expansion, Whitehouse Labs becomes one of the only facilities in the ...
Breaking Biology Technology:
(Date:4/5/2017)... 5, 2017  The Allen Institute for Cell Science ... a one-of-a-kind portal and dynamic digital window into the ... the first application of deep learning to create predictive ... lines and a growing suite of powerful tools. The ... and future publicly available resources created and shared by ...
(Date:4/4/2017)... April 4, 2017   EyeLock LLC , a ... the United States Patent and Trademark Office (USPTO) has ... the linking of an iris image with a face ... represents the company,s 45 th issued patent. ... very timely given the multi-modal biometric capabilities that have ...
(Date:3/30/2017)... KONG , March 30, 2017 The ... a system for three-dimensional (3D) fingerprint identification by adopting ground breaking ... into a new realm of speed and accuracy for use in ... at an affordable cost. ... ...
Breaking Biology News(10 mins):